Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia

pharmaceutical-technologyApril 14, 2017

Tag: dyskinesia , FDA

PharmaSources Customer Service